Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    15304395 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)
Conditions: Diffuse Large B-Cell Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: Ibritumomab Tiuxetan (Zevalin)
2 Recruiting Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
Conditions: Leukemia, B-cell;   Lymphoma, Hodgkins;   Lymphoma, Non-hodgkins;   Lymphoma, B-Cell
Interventions: Procedure: Allogeneic stem cell transplant;   Biological: Anti-CD19-chimeric-antigenreceptor- traduced T cell;   Drug: Cyclophosphamide;   Drug: Pentostatin

Indicates status has not been verified in more than two years